University of Oxford , Chemistry Research Laboratory, 12 Mansfield Road, Oxford OX1 3TA, U.K.
UCB Biopharma SPRL , 1420 Braine-L'Alleud, Belgium.
J Am Chem Soc. 2017 Jun 21;139(24):8267-8276. doi: 10.1021/jacs.7b03131. Epub 2017 Jun 12.
Molecules labeled with fluorine-18 (F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using the copper-mediated F-fluorination of aryl boron reagents with F-fluoride as a model reaction. This approach is based on a study examining how the presence of heterocycles commonly used in drug development affects the efficiency of F-fluorination for a representative aryl boron reagent, and on the labeling of more than 50 (hetero)aryl boronic esters. This set of data allows for the application of this derisking strategy to the successful radiosynthesis of seven structurally complex pharmaceutically relevant heterocycle-containing molecules.
带有氟-18(F)标记的分子用于正电子发射断层扫描,以可视化、描述和测量体内的生物过程。尽管最近在将 F 掺入芳烃方面取得了进展,但开发用于药物发现计划的放射性配体的通用且高效的方法仍然是一项重要任务。本综述描述了一种使用铜介导的芳基硼试剂的 F-氟化反应作为模型反应,对杂环正电子发射断层扫描(PET)放射性配体的放射合成进行风险评估的方法。该方法基于一项研究,该研究考察了在药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 F-氟化效率,以及对 50 多个(杂)芳基硼酸酯的标记。这组数据允许将这种风险评估策略应用于七种结构复杂的具有药物相关性的含杂环分子的成功放射合成。